# Safety and Efficacy Study of a Eye Drop for Eye Allergy

> **NCT00889330** · PHASE3 · COMPLETED · sponsor: **Vistakon Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** alcaftadine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00889330
- **Lead sponsor:** Vistakon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-05
- **Final completion:** —
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00889330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00889330, "Safety and Efficacy Study of a Eye Drop for Eye Allergy". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00889330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*